Preclinical and Clinical Development of Low Dose Methamphetamine for the Treatment of Traumatic Brain Injury

Abstract

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATEApril PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) AND ADDRESS(ES) PERFORMING ORGANIZATION REPORT NUMBERUniversity of Montana 32 Campus Dr. Missoula, MT 59812 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTThis proposal addresses additional preclinical characterization of low dose methamphetamine as a neuroprotective agent for TBI. We have previously demonstrated that treatment with methamphetamine within 12 hours after TBI significantly improved cognition and functional behavior in 2-3 month old male Wistar rats. These studies were intended to examine the therapeutic effects of methamphetamine in female and aged male rats. We also repeated a MRI time course study with the intent of determining if there was a dose response effect associated with methamphetamine induced white matter track remodeling. We have determined that female rats represent a poor model for TBI. Unlike humans, female rats have a 3-day estrous cycle. This means they are endogenously exposed to the neuroprotective effects of estrogen and progesterone before, during and after injury. This allows them to recover to near normal levels within a few weeks of after injury. In this context, it is not possible to observe any kind of drug effect on cognitive or behavioral outcomes. We have determined that methamphetamine does not exhibit a therapeutic effect in aged rats. A number of changes exist in aged rats that could account for this observation. First, they have reduced dopamine receptors. We have shown that methamphetamine-mediated neuroprotection is dependent, in part, on the activation of dopamine receptors. This reduction of dopamine receptors also contributes to a condition of chronic inflammation. We have shown that methamphetamine reduces neuroinlammatory signaling. Thus, the reduction of dopamine receptor mediated signaling could explain the loss of protectiv...